Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. by 媛뺤��꽍 et al.
Non–Laboratory-Based Self-Assessment Screening Score
for Non-Alcoholic Fatty Liver Disease: Development,
Validation and Comparison with Other Scores
Yong-ho Lee1, Heejung Bang2, Young Min Park3, Ji Cheol Bae4, Byung-Wan Lee1, Eun Seok Kang1,
Bong Soo Cha1, Hyun Chul Lee1, Beverley Balkau5,6, Won-Young Lee7*, Dae Jung Kim8,9*
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 2Division of Biostatistics, Department of Public Health Sciences, School of
Medicine, University of California Davis, Davis, California, United States of America, 3Department of Family Medicine, National Health Insurance Corporation Ilsan Hospital,
Goyang, South Korea, 4Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, South Korea, 5 Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Epidemiology of diabetes, obesity and chronic renal
disease over the lifecourse, Villejuif, France, 6University Paris-Sud, UMRS 1018, Villejuif, France, 7Division of Endocrinology and Metabolism, Department of Internal
Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 8Department of Endocrinology and Metabolism, Ajou University
School of Medicine, Suwon, South Korea, 9 Institute on Aging, Ajou University School of Medicine, Suwon, South Korea
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent and rapidly increasing disease worldwide; however, no
widely accepted screening models to assess the risk of NAFLD are available. Therefore, we aimed to develop and validate a
self-assessment score for NAFLD in the general population using two independent cohorts.
Methods: The development cohort comprised 15676 subjects (8313 males and 7363 females) who visited the National
Health Insurance Service Ilsan Hospital in Korea in 2008–2010. Anthropometric, clinical, and laboratory data were examined
during regular health check-ups and fatty liver diagnosed by abdominal ultrasound. Logistic regression analysis was
conducted to determine predictors of prevalent NAFLD and to derive risk scores/models. We validated our models and
compared them with other existing methods using an external cohort (N = 66868).
Results: The simple self-assessment score consists of age, sex, waist circumference, body mass index, history of diabetes and
dyslipidemia, alcohol intake, physical activity and menopause status, which are independently associated with NAFLD, and
has a value of 0–15. A cut-off point of $8 defined 58% of males and 36% of females as being at high-risk of NAFLD, and
yielded a sensitivity of 80% in men (77% in women), a specificity of 67% (81%), a positive predictive value of 72% (63%), a
negative predictive value of 76% (89%) and an AUC of 0.82 (0.88). Comparable results were obtained using the validation
dataset. The comprehensive NAFLD score, which includes additional laboratory parameters, has enhanced discrimination
ability, with an AUC of 0.86 for males and 0.91 for females. Both simple and comprehensive NAFLD scores were significantly
increased in subjects with higher fatty liver grades or severity of liver conditions (e.g., simple steatosis, steatohepatitis).
Conclusions: The new non–laboratory-based self-assessment score may be useful for identifying individuals at high-risk of
NAFLD. Further studies are warranted to evaluate the utility and feasibility of the scores in various settings.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is pathologically
defined as accumulation of fat, mainly triglycerides, in hepato-
cytes, with no evidence of significant alcohol consumption or other
secondary causes [1,2]. This includes the entire spectrum of fatty
liver conditions, ranging from simple hepatic steatosis through
steatohepatitis to cirrhosis. NAFLD is one of the most common
metabolic liver disorders, and its incidence is increasing rapidly.
The prevalence of NAFLD is between 6.3% and 33% depending
on the population [2–4], and is expected to rise in the future as the
rate of obesity increases, populations become older, and physical
activity levels decrease.
NAFLD is associated with serious complications and mortality,
and places a large burden on public healthcare systems, as well as
patients [5,6]. It not only impairs health-related quality of life, but
is also closely related to metabolic syndrome, dyslipidemia,
diabetes, and cardiovascular disease [5,7,8]. Subjects with NAFLD
demonstrated increased all-cause, cardiovascular and liver-related
mortality in general US [9], European [10] and Asian populations
[11].
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Considering the clinical impact of NAFLD on public health,
and its high prevalence, timely screening and detection could be
essential to avoid further NAFLD-related morbidity, reduce
healthcare costs, and promote early lifestyle interventions that
may prevent or delay deterioration of the disease [12]. As NAFLD
is usually asymptomatic, it is difficult to predict or determine
whether individuals have NAFLD in community settings. NAFLD
is diagnosed mostly using imaging modalities such as hepatic
ultrasound or computed tomography. These methods are expen-
sive, and can be complicated or inconvenient, and are thus not
practical or feasible in the general population. Therefore,
establishing a simple screening test or risk assessment tool could
be useful not only for identifying individuals at high-risk of
NAFLD, but also educating the general public about associated
risk factors [13]. A few risk-assessment algorithms have been
developed to identify individuals at high-risk of NAFLD [14–18].
Most were derived from relatively small samples (e.g., ,600
subjects) and lack external validation, and all models include
variables that are less practical or feasible, such as laboratory
profiles that require additional blood assays and/or complicated
equations that require calculators. These major barriers, which
prevent laypersons from using these models, may partly explain
why they have not been widely accepted in practice.
Therefore, the aim of our study was to develop and validate a
self-assessment score for NAFLD risk in the general population
using simple clinical parameters 2 including demographics,
anthropometrics and lifestyle risk factors 2 to provide a reliable
and easy tool usable by laypersons with or without the assistance of
a clinician. We also developed a more accurate and comprehen-
sive model that can further account for biochemical parameters
when this information is available. Finally, we compared the new
algorithm with existing models.
Materials and Methods
Ethics statement
The study protocol was approved by the institutional review
board of Ilsan Hospital (SU-YON 2013-02). Informed consent
requirement for this study was exempted by the institutional
review board because researchers only accessed the database for
analysis purposes, and personal information was not accessed.
Data Source and Subjects
The ‘development’ cohort, named the National Health Insur-
ance Service (NHIS) Registry, was established from 18765
individuals aged $20 years who visited the NHIS Ilsan Hospital
in Korea for comprehensive health examinations between 2008
and 2010, and was used for prediction modeling. Figure S1
illustrates a flow diagram of the study design. Subjects who met the
following criteria were excluded based on our protocol: (1) alcohol
consumption .140 g/week for males and 70 g/week for females
(N = 778); (2) positive serologic markers for hepatitis B (N = 752),
hepatitis C virus (N = 130), or human immunodeficiency virus
(N = 1); (3) presence of thyroid disease, including hyperthyroidism,
hypothyroidism, or thyroid hormone replacement therapy
(N = 118); (4) abnormal ultrasonographic liver findings (i.e.,
suspected hepatocellular carcinoma, hepatic mass, or signs of
Clonorchis sinensis) (N = 971); and/or (5) absence of questionnaire
data or anthropometric measurements (N = 1135). Ultimately,
15676 subjects (8313 males and 7363 females) were eligible for the
analysis.
The ‘external validation’ dataset was obtained from compre-
hensive health check-up data for Kangbuk Samsung Hospital from
2008, which have been described previously in detail [19]. Briefly,
66868 subjects aged $20 years (46896 males and 19972 females)
were selected for the validation study after applying the same set of
exclusion criteria.
Data and Measurements
We used demographic and personal and family medical history
data, and data on lifestyle/behavioral factors such as smoking and
alcohol consumption, physical activity, and anthropometrics.
Laboratory parameters were also measured in the morning after
overnight fasting for at least 8 h. Subjects previously diagnosed
with diabetes by a healthcare professional or taking anti-diabetic
drugs based on the health interview survey were classified as
having diabetes. Hypertension was defined as diagnosis by a
physician or treatment with antihypertensive medication. We
defined dyslipidemia according to the National Cholesterol
Education Program-Adult Treatment Panel III [20] as a total
cholesterol level of$200 mg/dL, a triglyceride level of$150 mg/
dL, a HDL cholesterol level of ,45 mg/dL in males or ,50 mg/
dL in females, a LDL cholesterol level of $130 mg/dL, or self-
reported use of prescribed cholesterol-lowering medication.
Smoking status was categorized as never, ex-, or current smoker
on the basis of lifetime exposure to cigarettes. Daily alcohol
consumption was quantitated by types of beverages, frequency of
drinking, and average amount of alcohol consumed on each
occasion, as described previously [21]. After excluding subjects
with excessive alcohol intake (as one of the exclusion criteria),
alcohol consumption was categorized as non-drinker or current
drinker. Exercise status was assessed by self-reported question-
naires that included questions about the duration, frequency, and
types of exercise. Regular exercise was then defined as engaging in
physical activity for at least 30 min twice or more per week.
In all subjects, abdominal ultrasonography (Sonoline Antares
MSC 2704 AB, Siemens Medical Solutions, Issaquah, WA) was
performed using a 3.5-MHz transducer by trained radiologists
who were blinded to the patients’ clinical and laboratory data. The
severity of fatty liver was categorized into three grades–mild,
moderate, and severe–based on standard criteria [22]. Then, we
finally defined the status of fatty liver as presence vs. absence.
Statistical Analyses
In the development and validation datasets, continuous
variables are expressed as the means 6 standard deviation (SD),
and categorical variables are presented as frequencies with
percentages. For model development, we performed multiple
logistic regression analyses with NAFLD as the endpoint. We
included a list of candidate predictors for NAFLD in an initial
regression model, with variables selected based on P-values,0.2 in
univariate analyses [23]. To create the ‘comprehensive’ model
from the initial model, backward elimination was performed until
we generated a final model with statistically significant covariates.
Then, we further derived a simpler, parsimonious model that
could be used by patients for self-assessment with or without input
from a clinician. In the ‘simple’ model, laboratory parameters
were avoided and continuous variables were categorized using
user-friendly cut-off points. We created a weighted scoring system
by assigning b coefficients in the final model to integer values,
while preserving monotonicity. Of note, in variable selection,
categorization, and scoring, clinical and practical judgment as well
as statistical significance were utilized [24]. We decided to develop
sex-specific models to account for the somewhat different risk
factors and cut-off points for different sexes. The goodness of fit of
the models was assessed using the Akaike information criterion
(AIC), and the discrimination ability by area under the receiver
operating characteristic curve (AUC).
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Next, we compared our new risk scores with the following
screening models for NAFLD using the development and
validation datasets: the Fatty Liver Index [14] and NAFLD liver
fat score [15] from European populations; the Hepatic steatosis
index [16]; and Park’s index for NAFLD [18] from Asian
populations. As evaluation measures, we computed sensitivity,
specificity, positive predictive value (PPV), negative predictive
value (NPV), likelihood ratios (LRs) (positive and negative), the
Youden index, and AUC [21,25,26]. Imputation was used to
handle missing data for fasting insulin (development dataset),
menopause status and alcohol consumption (validation dataset).
Additionally, we fitted the simple model (derived from the
development dataset) to (1) the validation dataset, to assess the
consistency of the results, and (2) subjects with excessive alcohol
intake (N = 691), to assess the sensitivity/robustness of its
discrimination ability. NAFLD fibrosis score [27] was used as a
surrogate index for defining poor condition of NAFLD (advanced
fibrosis). The formula is: NAFLD fibrosis score = 1.675+
0.0376age (years)+0.0946BMI (kg/m2)+1.136IFG/diabetes
(yes = 1, no = 0)+0.996AST/ALT ratio 0.0136platelet (6109/l)
0.666albumin (g/dl). Jonckheere-Terpstra test was used to
conduct trend analysis. Statistical analyses were conducted using
SAS version 9.2 (SAS Institute, Cary, NC), SPSS version 20.0
(SPSS, Chicago, IL) and MedCalc (version 13.1).
Results
Characteristics of subjects in the development and
validation datasets
The characteristics of the study subjects are summarized in
Table 1 according to NAFLD status. The prevalences of NAFLD
(based on ultrasonographic findings) were 41 and 30% in the
development and validation datasets, respectively. The higher
prevalence in the development dataset may be explained by the
higher mean age. In both datasets, subjects with NAFLD tended to
be older and more obese, to exercise less, and to have higher
laboratory values for metabolic factors, compared to those without
NAFLD. Furthermore, males, those with hypertension or diabetes,
and postmenopausal females were more likely to have NAFLD.
Development of comprehensive and self-assessment
models/scores for NAFLD
Table 2 describes the final2comprehensive and simple2
regression models derived from the development dataset. In the
Table 1. Characteristics of the study subjects.
Development dataset
(N=15676) P{
External validation
dataset (N=66868) P{
Normal (N=9221) NAFLD (N=6455) Normal (N=46896) NAFLD (N=19972)
Age (years) 46.1611.3 50.5611.2 ,0.001 41.868.7 43.768.7 ,0.001
Sex, M/F
(% female)
4054/5167 (56) 4259/2196 (34) ,0.001 21278/25618 (55) 15942/4030 (20) ,0.001
BMI (kg/m2) 22.362.5 25.962.8 ,0.001 22.462.6 25.962.8 ,0.001
Waist
circumference (cm)
78.767.4 88.667.2 ,0.001 76.967.7 86.867.7 ,0.001
Fasting
glucose (mg/dL)
90.5613.5 101.2623.8 ,0.001 92.9612.7 101.6621.7 ,0.001
Uric acid (mg/dL) 4.961.2 5.661.4 ,0.001 5.061.3 6.161.4 ,0.001
Total cholesterol
(mg/dL)
186.3633.0 201.5637.1 ,0.001 190.5632.0 207.0634.7 ,0.001
Triglycerides
(mg/dL)*
89.0654.3 155.46110.4 ,0.001 101.4658.2 176.36106.1 ,0.001
HDL cholesterol
(mg/dL)
51.0613.5 42.8610.6 ,0.001 58.1613.0 48.969.8 ,0.001
LDL cholesterol
(mg/dL)
117.5629.5 127.6635.0 ,0.001 105.7627.6 122.7630.1 ,0.001
AST (IU/L)* 22.9612.7 28.4614.8 ,0.001 22.569.4 28.0612.6 ,0.001
ALT (IU/L)* 20.0615.8 32.2622.7 ,0.001 20.6613.8 37.1623.5 ,0.001
Hypertension (%) 861 (9) 1489 (23) ,0.001 2081 (4) 2087 (10) ,0.001
Diabetes (%) 258 (3) 692 (11) ,0.001 1027 (2) 1449 (7) ,0.001
Regular exercise (%) 2824 (31) 1843 (29) 0.005 9258 (20) 3357 (17) ,0.001
Smoking history
(never/past/current)
5789/1490/1942 3024/1613/1818 ,0.001 33601/5192/8103 9858/3895/6219 ,0.001
Alcohol consumption
(%)
1388 (15) 977 (15) 0.886 NA NA NA
Menopause
(% of females)
1226 (24) 1219 (56) ,0.001 NA NA NA
*Log transformed.
{P values were calculated from t-tests for continuous variables and chi-squared tests for categorical variables, respectively.
M, male; F, female; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not available.
doi:10.1371/journal.pone.0107584.t001
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comprehensive model, age, alcohol consumption, and regular
exercise were significantly associated with NAFLD in males, while
diabetes and menopause were significantly associated with
NAFLD in females. WC, BMI, and laboratory covariates such
as fasting glucose, lipid profiles, uric acid, and liver enzymes were
significant predictors, regardless of sex. The comprehensive model
yielded an AUC of 0.86 for males and 0.91 for females. The score
derived from the comprehensive model (designated the ‘compre-
hensive score’) ranges from 0 to 100 and can be directly
interpreted as the ‘average’ probability of having the disease
among persons with similar risk factor profiles.
In the simple model, age, WC, BMI, diabetes, dyslipidemia, and
exercise were significant for both sexes (most P,0.001). Multiple
categories (with scores of 0 to 4) were introduced to capture the
risk gradient of obesity measures (BMI and WC), whereas other
risk factors were binary. The ‘simple or self-assessment score’ (0–
15) was developed from the simple model, where the seven risk
factors jointly yielded an AUC of 0.82 for males and 0.88 for
females. The AIC and AUC values of the various models are
summarized in Table S1.
External validation
We investigated the diagnostic characteristics of different
screening score cut-off points in the development and validation
datasets. For the comprehensive score, $40 was selected as the
cut-off point to define individuals with a high risk of NAFLD as it
gives the highest value for the Youden index (data not shown). For
the simple score, we selected a cut-off point of $8, which yielded
sensitivities of 75% and 68%, specificities of 71% and 85%, and
AUC values of 0.80 and 0.85 in males and females, respectively
(Table 3). The comprehensive score and simple score (in females)
yielded the highest overall test accuracy (reflected by the Youden
index) and the largest AUC in both datasets, while the
performance of the simple score (in males) was comparable in
performance of the other risk models. Loss of accuracy and
discrimination with the simple score was minimal, despite it not
relying on difficult health information or formulae. Comparison
analysis of AUC among screening models in the validation dataset
showed that the performance of comprehensive score and Fatty
liver index were superior to those of other models (Table S2).
When our simple model was refitted to the validation dataset,
similar results were obtained: all of the risk factors were statistically
significant, and the direction and magnitude of the associations
were comparable, with an AUC of 0.80 in males and 0.85 in
females (Table S3).
Figure 1 shows the prevalence of NAFLD according to total
simple score for each sex group in the development and validation
datasets. The prevalence of NAFLD increased as the risk scores
increased. Figure 2 provides a sample questionnaire for the risk
assessment of NAFLD that may be used by laypersons, as well as
healthcare providers.
Ancillary analyses
As a sensitivity analysis, we applied the simple score to the
subjects with excessive alcohol consumption (N = 691) who were
initially excluded from the analysis. The simple score yielded
similar AUCs (0.82 for males and 0.87 for females), suggesting that
the discriminatory ability was preserved, even in a specific
population highly susceptible to alcoholic fatty liver.
The simple and comprehensive scores were gradually increased
in subjects with higher fatty liver grades (determined by hepatic
ultrasound) (all P,0.001; Figure 3A and B). Furthermore, subjects
categorized as having advanced fibrosis based on NAFLD fibrosis
score [27] showed significantly higher simple and comprehensive
scores compared to other subjects with negative or intermediate
results from NAFLD fibrosis which denotes less likely to have
advanced fibrosis in their liver. (all P,0.001; Figure 3C and D).
These findings indicate that the present scores can reflect the
severity of fatty liver and be applied to discriminate advanced stage
of non-alcoholic steatohepatitis (NASH) from simple steatosis.
Discussion
We developed and validated models that could identify subjects
at high-risk of NAFLD. The simple model is based on
demographic, clinical, and anthropometric variables–age, WC,
BMI, diabetes, dyslipidemia, exercise, alcohol intake, and meno-
Figure 1. Estimated prevalence of NAFLD according to screening score: development and external validation datasets. A,
development dataset (N = 15676); B, external validation dataset (N = 66868).
doi:10.1371/journal.pone.0107584.g001
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pause status–while the comprehensive model additionally includes
laboratory parameters such as lipid and liver enzyme profiles.
Newly developed NAFLD screening models/scores may serve as a
doctor–patient communication tool and an initial step to identify
high-risk subjects, who can be referred for further blood assays or
imaging tests such as ultrasonography, possibly in conjunction with
preventive measures or early interventions to manage NAFLD.
Depending on the availability of health-related information and
targeted accuracy, either or both models may be used.
NAFLD is regarded not only as a common disease in Western
societies but also as an emerging problem in many Asian countries
[28]. That the prevalence of NAFLD can further increase as the
number of obese people in Asia increases is supported by the
findings that 65 and 85% of subjects with a BMI of 30–40 and $
40 kg/m2, respectively, had NAFLD [29]. Despite its high
prevalence and potential impact, recent studies highlighted that,
even among high-risk patients, 87% of people did not know they
had NAFLD [30] and 51% of healthy potential liver donors were
incidentally confirmed as having NAFLD by liver biopsy [31],
indicating that alarming proportions of patients with NAFLD are
unaware of their illness and are undiagnosed. Therefore, a simple
risk score that can efficiently and effectively screen high-risk
individuals for NAFLD in communities, as well as in clinical
settings, could help improve personal and population health, and
public awareness and education about this less known disease.
Notably, even in developed countries such as Hong Kong, 83% of
the general population had never heard of NAFLD and 78% of
respondents who understood the term had a misconception about
Figure 2. Sample self-assessment screening questionnaire.
doi:10.1371/journal.pone.0107584.g002
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this common condition [13]. We speculate that this is also a
common phenomenon in other settings.
To date, studies have focused on searching for novel biomarkers
or developing models that can predict progression of NAFLD to
NASH [27,32]. Although NASH is a more serious liver disorder
that may progress to cirrhosis, early detection of mild forms of
NAFLD, such as simple steatosis, is also an important and
promising field from a public health perspective. As fatty liver is a
more prevalent but reversible disease, identification of individuals
at high-risk of NAFLD through proper risk assessment and
subsequent lifestyle modification may restore their hepatic
condition and prevent progression to NASH or other related
morbidities.
Our study has several distinguishable features. First, to our
knowledge, the model was developed based on the largest general
population with hepatic ultrasound-defined NAFLD. Many studies
examined relatively small numbers of subjects [14,15,33] or used
surrogate markers such as liver enzymes to predict NAFLD [34];
however, a significant number of patients with NAFLD have
normal liver enzyme levels. Second, our simple score is easy to use
and is based on readily available variables. Thus, laypersons can
calculate and learn about their own risk–with or without help from
healthcare providers–and can initiate a discussion with their
Figure 3. Average scores for the simple and comprehensive models according to fatty liver grade determined by hepatic
ultrasound or NAFLD fibrosis score. Average scores for A) the simple model or B) the comprehensive model according to fatty liver grade
determined by hepatic ultrasound. All P values of comparison between any groups are ,0.001. *P for trend are ,0.001. Average scores for C) the
simple model or D) the comprehensive model according to the fatty liver conditions defined by NAFLD fibrosis score. Subjects with negative results
by NAFLD fibrosis score (N= 12046) could be excluded from having advanced fibrosis and subjects with positive results of NAFLD fibrosis score
(N= 131) are highly likely to have advanced fibrosis. All P values of comparison between any groups are ,0.001. *P for trend are ,0.001. Data are
shown as mean with SD.
doi:10.1371/journal.pone.0107584.g003
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physician if necessary. Third, the score includes modifiable risk
factors such as obesity (defined by WC and BMI), exercise, and
alcohol consumption, so users can learn about important risk
factors and could be motivated to change or improve their
lifestyle/health habits. For example, if subjects at high-risk of
NAFLD reduce their body weight, start exercising regularly, and
abstain from drinking, their risk scores could decrease. Lastly, the
sensitivity analysis indicated that the simple score is well applicable
to predict hepatic steatosis in subjects with heavy drinking as well.
This may be explained by the findings that fatty liver is more
strongly affected by obesity than by excessive alcohol consumption
[35].
Of note, our scores are sex-specific, unlike in previous models.
WC, which reflects central obesity, had a stronger association with
NAFLD in males than in females, while BMI, which is an index of
overall obesity, showed a stronger association with NAFLD in
females compared to males in our two independent datasets. This
observation may be due to male subjects having more visceral
adipose tissue than females, and suggest that males may be more
susceptible to visceral fat deposition, which leads to accumulation
of fat in the liver [36]. In females, the OR was dramatically
increased in subjects aged over 50 years. This increase was offset
by adjustment for menopause status in the logistic model,
indicating that menopause may be more influential than age for
NAFLD in females. This finding is supported by epidemiologic
and experimental evidence that insulin resistance and visceral fat
levels are significantly increased in postmenopausal females [37],
and that estrogen protects against hepatic steatosis [38]. Among
biochemical variables, ALT and AST made the greatest contri-
bution to the prediction of NAFLD, followed by triglycerides,
consistent with previous findings [14–16,18]. In addition, one of
the components of the comprehensive model was serum uric acid
level, which has been proposed to be a risk factor for NAFLD [39].
The present study has some potential limitations, which could
be addressed by future investigations. First, diagnosis of NAFLD
by ultrasonography could underestimate the actual prevalence of
NAFLD in this population. Second, as this risk score was derived
from a cross-sectional study, its use for the prediction of future
development of NAFLD may be limited. However, cross-sectional
data are well suited for screening for prevalent, undiagnosed cases,
which generally precedes the prediction of incident, new cases.
Third, the models/scores were derived from the general popula-
tion of an Asian ethnic group, which may limit their generaliz-
ability and applicability to non-Asian or other Asian populations.
Notably, considering the differences in the definitions of obesity
between Western and Asian countries, cut-off points for factors
related to obesity (e.g., WC and BMI) will be subject to
modifications depending on the population, or new models may
be warranted [40].
Conclusions
The present results demonstrate that new screening scores for
NAFLD performed well compared to existing models, and has
some notable advantages (e.g., no laboratory tests required, self-
assessment). Our simple self-assessment score for NAFLD risk
could be useful for both primary care practitioners and laypersons
as a screening and counseling tool. Future research is warranted to
verify the effectiveness, usefulness, and feasibility of our models in
various practical settings, and potentially to revise or adapt them
for other populations.
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